Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
| Author | |
|---|---|
| Abstract |
:
Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2 metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challenging. We report the results of combined ixabepilone and carboplatin in a single-arm phase II trial. |
| Year of Publication |
:
2018
|
| Journal |
:
Clinical breast cancer
|
| Volume |
:
18
|
| Issue |
:
1
|
| Number of Pages |
:
e89-e95
|
| ISSN Number |
:
1526-8209
|
| URL |
:
https://linkinghub.elsevier.com/retrieve/pii/S1526-8209(16)30521-3
|
| DOI |
:
10.1016/j.clbc.2017.07.002
|
| Short Title |
:
Clin Breast Cancer
|
| Download citation |
